Oncology

Review top news and interview highlights from the week ending January 26, 2024.

The internal medicine resident physician at University of Kansas Medical Center also discussed highlights from the ASH 2023 meeting.

BriaCell also shared specific positive data from one patient with proptosis and ocular pain.

The European Medicines Agency Committee for Advanced Therapies will likewise hold a SAG-O meeting regarding the Type II variation application for the CAR-T in the EU.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The immune therapy is a replication-incompetent human tumor cell line designed to conjugate to and prime resting natural killer cells.

The associate professor at Fred Hutch Cancer Center discussed trends he observed in the field in 2023 and at ASH 2023.

The postdoctoral researcher at Laboratory for Translational Cancer Immunology, Ludwig-Maximilians-Universität München, discussed research he was excited to see at ASH 2023 and in the field in general.

The agency does not have plans for an advisory committee meeting to discuss obe-cel, which is an investigational autologous CD19-directed CAR-T therapy.

The trial is assessing satri-cel CAR T-cell therapy, which is currently on clinical hold due to CMC concerns.

Kiromic announced that the first patient had been dosed with the gamma delta cell therapy in December 2023.

TAC01-CLDN18.2 integrates TAC, Triumvira’s proprietary chimeric receptor that is intended to activate and direct T-cells against tumor cells.

Review top news and interview highlights from the week ending January 19, 2024.

Dose level 3 showed the most efficacy and has been selected for the phase 2 portion of the trial.

The chief hematology/oncology fellow at University of Chicago discussed further research his center is working on with cell therapy in B-cell acute lymphoblastic leukemia.

Hemogenyx originally submitted the IND to the FDA in May 2023 with the intention of gaining clearance for a phase 1 clinical trial in acute myeloid leukemia.

The cofounder, executive vice president, and chief medical officer, CLL Society, discussed unmet needs that remain for people with CLL and how the society is working to advance research in the field.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Three of CARsgen’s CAR therapies are currently on clinical hold due to CMC questions.

The associate professor at Peter MacCallum Cancer Centre discussed highlights from the 2023 ASH meeting.

Review top news and interview highlights from the week ending January 12, 2024.

The internal medicine resident physician at University of Kansas Medical Center encouraged centers to actively address female minority paper authorship.

Atara plans to submit a BLA for tab-cel, approved in Europe, in the second quarter of 2024.

The associate professor at Fred Hutch Cancer Center discussed data from a retrospective analysis of patients treated with tisa-cel, axi-cel, or liso-cel.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.